In Brief: New Warning for Extended-Release Stimulants for ADHD
The FDA now requires that the labels of all extended-release stimulants used for treatment of attention-deficit/hyperactivity disorder (ADHD) include a warning about the risks of weight loss and other adverse effects associated with their use in children <6 years old. The labels of all stimulants used for treatment of ADHD already contain a boxed warning about the high risk of abuse and dependence associated with their use.
Publication Details
- Journal
- The medical letter on drugs and therapeutics/The medical letter
- Published
- 2025-08-18
- DOI
- https://doi.org/10.58347/tml.2025.1735f
- Primary Topic
- Attention Deficit Hyperactivity Disorder
- Type
- article
- Field-Weighted Citation Impact
- 0.00